Abstract
Abstract
Detection of antihypertensive drugs in biological samples is an important tool to assess the adherence of hypertensive patients. Urine and serum/plasma screenings based on qualitative results may lead to misinterpretations regarding drugs with a prolonged detectability. The aim of the present study was to develop a method that can be used for therapeutic drug monitoring (TDM) of antihypertensive drugs with focus on adherence assessment. Therefore, a method for quantification of four diuretics and four β-blockers using high-performance liquid chromatography-mass spectrometric analysis (LC-MS/MS) of combined acidic and basic serum extracts was developed and validated. The method was applied to 40 serum samples from 20 patients in a supervised medication setting (trough and peak serum samples). Literature data on therapeutic concentration ranges, as well as dose-related drug concentrations (calculated from data of pharmacokinetic studies) were used to evaluate adherence assessment criteria. Concentrations were measured for bisoprolol (n = 9 patients), metoprolol (n = 7), nebivolol (n = 1), canrenone (n = 2, metabolite of spironolactone), hydrochlorothiazide (n = 10) and torasemide (n = 8). The measured concentrations were within the therapeutic reference ranges, except for 24% of the samples (mainly β-blockers). In contrast, all measured concentrations were above the lower dose-related concentration (DRC), which appears superior in evaluating adherence. In conclusion, the quantitative analysis of antihypertensive drugs in serum samples and its evaluation on the basis of the individually calculated lower DRC is a promising tool to differentially assess adherence. This method could possibly detect a lack of adherence or other causes of insufficient therapy more reliably than qualitative methods.
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Robert Koch-Institute. Health in Germany – the most important trends. Available at,
https://www.rki.de/EN/Content/Health_Monitoring/Health_Reporting/HealthInGermany/Health-in-Germany_most_important_developments.pdf?__blob=publicationFile
(2016).
2. Wilkins, E. et al. European Cardiovascular Disease Statistics 2017. European Heart Network, 1–192 (2017).
3. Sabaté, E. Adherence to long-term therapies. Evidence for action. Available at,
https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1
(2003).
4. Mennini, F. S. et al. Cost of poor adherence to anti-hypertensive therapy in five European countries. The European journal of health economics 16, 65–72,
https://doi.org/10.1007/s10198-013-0554-4
(2015).
5. Kronish, I. M. et al. Meta-Analysis: Impact of Drug Class on Adherence to Antihypertensives. Circulation 123, 1611–1621,
https://doi.org/10.1161/CIRCULATIONAHA.110.983874
(2011).
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献